enocitabine has been researched along with Chromosomal Translocation in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amoh, Y; Katsuoka, K; Mukai, H; Niiyama, S; Watarai, A | 1 |
| Huh, J; Jung, CW; Kim, DH; Kim, H; Kim, HJ; Kim, SH; Kim, YK; Lee, WS; Min, WS; Moon, JH; Mun, YC; Park, J; Shin, MG; Sohn, SK; Won, JH | 1 |
| Ahn, HK; Jung, CW; Kim, DH; Kim, H; Kim, HJ; Kim, KH; Kim, SH; Kim, YK; Lee, KO; Lee, WS; Min, WS; Moon, JH; Mun, YC; Park, CH; Park, J; Sohn, SK | 1 |
3 other study(ies) available for enocitabine and Chromosomal Translocation
| Article | Year |
|---|---|
Cutaneous myeloid sarcoma presenting as grey pigmented macules.
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 7; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Sarcoma, Myeloid; Skin; Skin Neoplasms; Skin Pigmentation; Translocation, Genetic; Treatment Outcome | 2012 |
A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Genome-Wide Association Study; Humans; Idarubicin; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-kit; Remission Induction; Translocation, Genetic; Young Adult | 2012 |
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Core Binding Factor Alpha 2 Subunit; Core Binding Factors; Cytarabine; Disease-Free Survival; Exons; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Korea; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Point Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; RUNX1 Translocation Partner 1 Protein; Transcription Factors; Translocation, Genetic; Treatment Outcome; Young Adult | 2013 |